Geneva, July 14 -- International Clinical Trials Registry received information related to the study (ISRCTN81435672) titled 'Precision medicine Adaptive Network platform Trial in Hypoxaemic acutE respiratory failuRe' on July 2.
Study Type: Interventional
Study Design:
Open randomized controlled parallel-group adaptive platform trial (Efficacy)
Primary Sponsor: Imperial College London
Condition:
Critical illnesses including acute respiratory disease syndrome and pandemic infection
Respiratory
Intervention:
Simvastatin:
Simvastatin may help repair the lungs by reducing inflammation and repairing the blood vessels in the lungs. Simvastatin will be administered at a dose of 80 mg once daily via the enteral route until study day 28 o...